Septerna (NASDAQ:SEPN) Price Target Raised to $50.00

Septerna (NASDAQ:SEPN) had its target price lifted by Wells Fargo & Company from $48.00 to $50.00 in a research report released on Wednesday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

SEPN has been the topic of several other research reports. Truist Financial lifted their price objective on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Stifel Nicolaus set a $49.00 target price on Septerna in a report on Tuesday. Guggenheim raised their price target on Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research note on Friday, July 17th. Finally, HC Wainwright boosted their price objective on Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.33.

Septerna Price Performance

Shares of NASDAQ SEPN opened at $44.50 on Wednesday. The stock has a market capitalization of $2.08 billion, a P/E ratio of -82.41 and a beta of 2.29. Septerna has a one year low of $10.74 and a one year high of $51.10. The firm’s 50 day simple moving average is $35.83 and its two-hundred day simple moving average is $29.64.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. The company had revenue of $26.75 million during the quarter, compared to analysts’ expectations of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. As a group, equities analysts expect that Septerna will post -1.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Septerna news, COO Elizabeth Bhatt sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the completion of the transaction, the chief operating officer owned 174,209 shares of the company’s stock, valued at $7,665,196. This represents a 12.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Daniel D. Long sold 3,334 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $34.47, for a total value of $114,922.98. Following the completion of the sale, the senior vice president owned 96,412 shares of the company’s stock, valued at approximately $3,323,321.64. This trade represents a 3.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 72,828 shares of company stock valued at $2,684,314 over the last ninety days. 5.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Septerna

A number of hedge funds and other institutional investors have recently made changes to their positions in SEPN. Jupiter Topco LLC bought a new stake in Septerna in the second quarter valued at $43,723,000. Elmind Capital LP purchased a new position in Septerna during the 2nd quarter valued at $1,655,880,000. ADAR1 Capital Management LLC bought a new position in Septerna in the 2nd quarter worth $31,506,000. Primecap Management Co. CA purchased a new stake in shares of Septerna in the 2nd quarter worth about $39,096,000. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Septerna in the 2nd quarter worth about $298,000.

Septerna News Roundup

Here are the key news stories impacting Septerna this week:

• Positive Sentiment: HC Wainwright significantly improved its Septerna earnings outlook, reducing its projected FY2026 loss to $1.15 per share from $2.17 and its FY2027 loss to $1.41 from $3.21. The firm retained a “Buy” rating and a $60 price target, suggesting analysts expect improved financial performance. HC Wainwright forecasts strong price appreciation for Septerna
• Positive Sentiment: HC Wainwright also raised its quarterly 2026 and 2027 EPS forecasts, with projected losses narrowing across every period. The revisions indicate better-than-expected operating trends or a more favorable development outlook for the clinical-stage biotechnology company. HC Wainwright earnings estimate revisions
• Positive Sentiment: JonesTrading raised its price target from $43 to $62 and assigned a “Buy” rating, while Wells Fargo increased its target from $48 to $50 and maintained an “Overweight” rating. These actions reinforce a favorable Wall Street view following Septerna’s recent earnings beat. JonesTrading raises Septerna price target
• Positive Sentiment: Septerna’s latest quarterly results exceeded expectations: the company reported a $0.29-per-share loss versus the anticipated $0.43 loss, while revenue of $26.75 million topped the $19.22 million consensus estimate. Septerna shares rise on better-than-expected earnings
• Negative Sentiment: COO Elizabeth Bhatt sold 25,000 shares for approximately $1.1 million at an average price of $44, reducing her ownership by 12.55%. She still holds 174,209 shares, but the insider sale could weigh on sentiment—particularly after the stock’s strong recent advance. Septerna COO insider share sale

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.